Merck & Company (NYSE: MRK) has reported impressive earnings results for the second quarter of 2022. However, shares of the company declined 1.4% on Thursday, largely due to the overall pessimism in the market over the drug pricing bill. The pharmaceutical giant saw its adjusted earnings rise to $1.87 per share in the second quarter of 2022 from 61 cents per share in the year-ago quarter. The metric also surpassed analysts’ estimates of $1.70 per share. Merck’s revenues for the reported quarter came in at $14.59 billion, up 28% year-over-year reported and 31% on a constant currency (cc) basis. The figure easily surpassed expectations of $13.90 billion.
https://www.tipranks.com/news/merck-posts-upbeat-q2-results-drug-pricing-bill-shakes-investor-confidence?utm_source=advfn.com&utm_medium=referral
Merck (NYSE:MRK)
Historical Stock Chart
Von Sep 2022 bis Okt 2022 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
Von Okt 2021 bis Okt 2022 Click Here for more Merck Charts.